Better Therapeutics, Inc.

Better Therapeutics, Inc. (Nasdaq: BTTX) is a digital therapeutics company focused on developing prescription digital therapeutics for cardiometabolic diseases, including type 2 diabetes. The company completed its de-SPAC merger with Mountain Crest Acquisition Corp. II, sponsored by Mountain Crest Capital LLC, in October 2021, becoming a publicly traded entity in the digital health sector. Its lead candidate, BT-001, aimed to address metabolic conditions through a software-based behavioral intervention approach requiring FDA authorization. As of its 10-Q filing in November 2023, BTTX remained in a post-merger operational phase navigating the commercial and regulatory challenges common to the prescription digital therapeutics industry. Sign up for full data, filing history, and deal analytics on SpacDesk.